The role of 2‐chlorodeoxyadenosine in the treatment of patients with refractory angioimmunoblastic lymphadenopathy with dysproteinemia

Sallah, Sabah; Wehbie, Robert S.; Lepera, Pamela; Sallah, Waddah; Bobzien, William

doi:10.1046/j.1365-2141.1999.01139.x

Cited by 27 publications

(13 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sallah et al reported an overall response rate of 60% with a 20% CR rate; our previous reports demonstrated a 70% overall response rate with a CR rate of 11%. 13,14 These findings led us to conclude that gemcitabine has the highest activity with acceptable toxicity in previously treated patients with CTCL. For this reason, we decided to use gemcitabine as the frontline treatment of CTCL to evaluate tumor response, as well as the safety and duration of response.…”

Section: Discussionmentioning

confidence: 99%

“…Several authors have reported satisfactory results using purine analogs in the treatment of different types of recurrent or refractory T-cell malignancies. 14,23,24 Kurzrock et al reported results using pentostatin in 28 CTCL patients; the overall response rate was 71% and the most common side effects were granulocytopenia, nausea, and nonneutropenic fever. 25 Other studies examining cladribine, fludarabine, and gemcitabine as single agents in pretreated CTCL patients reported an overall response rate of 24 -47% for cladribine and fludarabine.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Gemcitabine as frontline treatment for cutaneous T‐cell lymphoma

Marchi

Alinari

Tani

et al. 2005

Cancer

142

View full text Add to dashboard Cite

BACKGROUNDBased on the activity of gemcitabine in heavily pretreated patients with cutaneous T‐cell lymphoma (CTCL), the objective of the current study was to determine the role of gemcitabine in the treatment of patients with advanced, untreated CTCL.METHODSBetween June 2002 and February 2004, 32 untreated patients with mycosis fungoides (MF) (n = 26 patients); peripheral T‐cell lymphoma, unspecified (PTCLU) with exclusive skin involvement (n = 5 patients); and Sezary syndrome (SS) (n = 1 patient) were enrolled in a 7‐institution, Phase II trial and treated with gemcitabine. This drug was given on Days 1, 8, and 15 of a 28‐day schedule at a dose of 1200 mg/m2 intravenously over 30 minutes for a total of 6 cycles.RESULTSOf the 32 patients studied, 7 (22%) achieved a complete response (CR) and 17 (53%) achieved a partial response (PR), whereas the remaining 8 patients showed no benefit from the treatment. Five of the CRs were confirmed histologically. The CR and PR rates were found to be the same for patients with MF and PTCLU, respectively. The median duration of CR was 10 months (range, 4–22 mos). Treatment appeared to be well tolerated; hematologic toxicity was mild and no nausea/emesis or organ toxicity was noted.CONCLUSIONSThe results of the current Phase II study demonstrate the activity of gemcitabine as a single agent in untreated CTCL patients. Further studies using gemcitabine in combination, either contemporary or sequentially, with other drugs in patients with advanced stage, untreated CTCL are needed. Cancer 2005. © 2005 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Gemcitabine as frontline treatment for cutaneous T‐cell lymphoma

Marchi

Alinari

Tani

et al. 2005

Cancer

142

View full text Add to dashboard Cite

show abstract

“…Numerous treatments have some efficacy in the management of AITL, but to date there is no consensus about which regimen is best. Because of unsatisfactory results with standard therapy, numerous small studies with mixed results have explored treating AITL with alternative agents such as cyclosporine [17], fludarabine [18], cladribine [19], alemtuzumab [20], methotrexate [21], and thalidomide [22]. Some studies have shown that AITL can be effectively treated with high-dose chemotherapy followed by autologous HSCT [23].…”

Section: To the Editormentioning

confidence: 99%

A suspicion of chikungunya leading to a diagnosis of angioimmunoblastic T-cell lymphoma

2009

View full text Add to dashboard Cite

“…Mortality has been reported as high as 60%, usually due to infections despite treatment with chemotherapy regimens. [27][28][29][30] The etiology of the AILD is unknown. Association with previous medications such as antibiotics and anticonvulsants and viral infections has been reported.…”

Section: Clinical Presentationmentioning

confidence: 99%

Atypical Lymphoproliferative Diseases

Greiner¹

2000

Hematology

View full text Add to dashboard Cite

This review addresses the clinical presentation, pathology, and therapy of several uncommon lymphoid proliferations. Because these lymphoproliferations span the characteristics of reactive polymorphous proliferations to clonal malignant neoplasms, they are often difficult to diagnose and treat effectively.In Section I, Dr. Greiner describes the pathology of the spectrum of atypical lymphoid disorders including Castleman's disease, angioimmunoblastic lymphadenopathy, lymphadenopathy in autoimmune diseases, posttransplant lymphoproliferative disorders, and X-linked lymphoproliferative disorder. The relationship to Epstein-Barr virus (EBV) and human herpsesvirus-8 (HHV-8) is discussed, and molecular diagnostic assays and principles for obtaining proper diagnostic evaluation are emphasized.In Section II, Dr. Armitage presents a practical approach to the management of Castleman's disease. The discussion includes the importance of confirmation of the histological diagnosis and careful staging evaluation, therapeutic options, and the increased risks for infection and lymphoma. The appropriate roles of surgical excision, corticosteroids, and combination chemotherapy are addressed along with alternative strategies such as anti-interleukin-6 and bone marrow transplantation.In Section III, Dr. Gross reviews the treatment of EBV-associated lymphoproliferative disorders in primary immunodeficiencies and in post-transplant patients. He gives an update on the recent molecular discoveries in X-linked lymphoproliferative disorder. Preliminary results of a phase II trial of low-dose cyclophosphamide in posttransplant lymphoproliferative disorders and the use of GM-CSF as preemptive therapy are presented.

show abstract

The role of 2‐chlorodeoxyadenosine in the treatment of patients with refractory angioimmunoblastic lymphadenopathy with dysproteinemia

Cited by 27 publications

References 11 publications

Gemcitabine as frontline treatment for cutaneous T‐cell lymphoma

Gemcitabine as frontline treatment for cutaneous T‐cell lymphoma

A suspicion of chikungunya leading to a diagnosis of angioimmunoblastic T-cell lymphoma

Atypical Lymphoproliferative Diseases

Contact Info

Product

Resources

About